Les maladies neurologiques augmentent-elles le risque ?
Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs.
Maladies neurologiquesSensibilitéRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques voltage-dépendants : Questions médicales les plus fréquentes",
"headline": "Bloqueurs de canaux sodiques voltage-dépendants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bloqueurs de canaux sodiques voltage-dépendants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques",
"url": "https://questionsmedicales.fr/mesh/D026941",
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques",
"code": {
"@type": "MedicalCode",
"code": "D026941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.720"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"alternateName": "Voltage-Gated Sodium Channel Blockers",
"code": {
"@type": "MedicalCode",
"code": "D061567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "William A Catterall",
"url": "https://questionsmedicales.fr/author/William%20A%20Catterall",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA 98195, USA. Electronic address: wcatt@uw.edu."
}
},
{
"@type": "Person",
"name": "Piyasuda Pukkanasut",
"url": "https://questionsmedicales.fr/author/Piyasuda%20Pukkanasut",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Sadanandan E Velu",
"url": "https://questionsmedicales.fr/author/Sadanandan%20E%20Velu",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Tamer M Gamal El-Din",
"url": "https://questionsmedicales.fr/author/Tamer%20M%20Gamal%20El-Din",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA, United States."
}
},
{
"@type": "Person",
"name": "Christopher L-H Huang",
"url": "https://questionsmedicales.fr/author/Christopher%20L-H%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Hopkins Building, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QW, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy.",
"datePublished": "2023-08-06",
"url": "https://questionsmedicales.fr/article/37586927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clcc.2023.08.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.",
"datePublished": "2022-11-09",
"url": "https://questionsmedicales.fr/article/36351568",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.14724"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.",
"datePublished": "2022-07-17",
"url": "https://questionsmedicales.fr/article/35963771",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clml.2022.07.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.",
"datePublished": "2022-09-05",
"url": "https://questionsmedicales.fr/article/36102865",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/DCR.0000000000002600"
}
},
{
"@type": "ScholarlyArticle",
"name": "PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).",
"datePublished": "2022-09-10",
"url": "https://questionsmedicales.fr/article/36099671",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2022.07.027"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002317"
},
{
"@type": "ListItem",
"position": 6,
"name": "Bloqueurs de canaux sodiques",
"item": "https://questionsmedicales.fr/mesh/D026941"
},
{
"@type": "ListItem",
"position": 7,
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"item": "https://questionsmedicales.fr/mesh/D061567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bloqueurs de canaux sodiques voltage-dépendants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?\nQuels tests sont utilisés pour évaluer l'effet des bloqueurs ?\nQuels symptômes indiquent une surdose de bloqueurs ?\nComment différencier les types de bloqueurs de canaux ?\nQuels antécédents médicaux sont pertinents pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Combined+Modality+Therapy#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les symptômes d'une intoxication aiguë ?\nComment se manifestent les effets secondaires des bloqueurs ?\nQuels signes indiquent une réaction allergique ?\nLes bloqueurs affectent-ils la respiration ?\nQuels symptômes neurologiques peuvent apparaître ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Combined+Modality+Therapy#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment prévenir les effets indésirables des bloqueurs ?\nQuelles précautions doivent être prises avant la prescription ?\nLes patients doivent-ils être informés des risques ?\nComment éviter les interactions médicamenteuses ?\nQuelles sont les recommandations pour les patients à risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Combined+Modality+Therapy#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quel est le traitement d'une surdose de bloqueurs ?\nComment gérer les effets secondaires des bloqueurs ?\nQuels médicaments peuvent interagir avec les bloqueurs ?\nLes bloqueurs sont-ils utilisés en anesthésie ?\nQuelle est l'importance de la surveillance pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Combined+Modality+Therapy#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quelles complications peuvent survenir avec les bloqueurs ?\nComment les complications sont-elles gérées ?\nLes complications sont-elles fréquentes ?\nQuels facteurs augmentent le risque de complications ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Combined+Modality+Therapy#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les principaux facteurs de risque ?\nComment l'âge influence-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'usage de drogues illicites est-il un facteur de risque ?\nLes maladies neurologiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Combined+Modality+Therapy#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'historique médical, les symptômes cliniques et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'effet des bloqueurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des électrocardiogrammes et des tests de conduction nerveuse peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de bloqueurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, une arythmie cardiaque et une dépression respiratoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment différencier les types de bloqueurs de canaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse des effets cliniques et des mécanismes d'action aide à les différencier."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont pertinents pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques ou neurologiques sont cruciaux pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une intoxication aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des nausées, des troubles de la vision et des convulsions."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les effets secondaires des bloqueurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des étourdissements, des maux de tête et des troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons et un gonflement peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "Les bloqueurs affectent-ils la respiration ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner une dépression respiratoire dans les cas graves."
}
},
{
"@type": "Question",
"name": "Quels symptômes neurologiques peuvent apparaître ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, des troubles de la conscience et des paralysies peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des bloqueurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prescription appropriée et une éducation du patient sont essentielles pour prévenir les effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles précautions doivent être prises avant la prescription ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicaux et les allergies du patient est crucial avant la prescription."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des risques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients des risques et des signes d'intoxication est essentiel."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen minutieux des médicaments prescrits et des antécédents est nécessaire pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les patients à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients à risque doivent être suivis de près et éduqués sur les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quel est le traitement d'une surdose de bloqueurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des soins de soutien, l'administration de charbon actif et des antidotes si disponibles."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des bloqueurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique l'ajustement de la dose ou le changement de médicament selon les symptômes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent interagir avec les bloqueurs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les antidépresseurs et les anesthésiques peuvent interagir."
}
},
{
"@type": "Question",
"name": "Les bloqueurs sont-ils utilisés en anesthésie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains bloqueurs de canaux sodiques sont utilisés pour induire une anesthésie locale."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance pendant le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter les effets indésirables et ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les bloqueurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des arythmies, des convulsions et des défaillances respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une intervention rapide et un traitement symptomatique."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, surtout en cas de surdose ou d'interactions."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge avancé, les maladies cardiaques et l'utilisation concomitante d'autres médicaments augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance attentive et une éducation adéquate peuvent aider à prévenir certaines complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques, l'âge et l'utilisation d'autres médicaments sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées ont un risque accru de complications en raison de la polypharmacie et de la fragilité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques ou neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'usage de drogues illicites est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage de certaines drogues peut interagir avec les bloqueurs et augmenter le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les maladies neurologiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs."
}
}
]
}
]
}
Survival rates in early-stage rectal cancer patients have increased over the past few decades. Societies such as the National Comprehensive Cancer Network (NCCN), American Cancer Society (ACS), Americ...
We aimed to analyze the radiation dose and compare survival among combined modality therapy using modern radiation techniques for patients with esophageal squamous cell carcinoma (ESCC)....
This retrospective study included patients with clinically staged T1-4N0-3M0 ESCC from 2014 to 2018. Patients who received combined modality therapies with curative intent were enrolled. The overall s...
Of the 259 patients, 141 (54.4%) received definitive concurrent chemoradiotherapy (DCCRT); 67 (25.9%) underwent neoadjuvant chemoradiotherapy followed by surgery (NCRT+S); 51 (19.7%) obtained surgery ...
Our results suggest that NCRT+S can provide a favorable survival for patients with ESCC, especially in patients who achieved pCR. The optimal radiation dose might be 55-60 Gy for patients receiving DC...
The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT). Recent treatment de-escalation tria...
This study used a cost-effectiveness Markov model simulating 5 year outcomes for 1 million patients with early-stage HL treated with either PET-directed therapy consisting of 2 cycles of ABVD chemothe...
We found that PET-directed therapy and CMT strategies were associated with costs of $47,362 and $41,167, respectively. The CMT strategy was equally as effective as the PET-directed therapy strategy wi...
For patients with early-stage HL, CMT is the cost-effective strategy as compared with PET-directed therapy....
There is limited knowledge on long-term bowel, sexual, and urinary function after combined modality therapy for anal squamous-cell cancer....
This study aimed to evaluate long-term changes in patients treated with combined modality....
This was a retrospective study of prospectively collected patient-reported outcome surveys....
This study was conducted at a single institution....
There were 143 patients with stage I to III anal cancer who were treated with chemoradiation and had completed the survey....
This study included patient-reported outcomes reflecting bowel, sexual, and urinary function....
Thirty-nine percent of patients had major low anterior resection syndrome at baseline. Major low anterior resection syndrome remained stable (38%; 95% CI, 31%-46%) with no change over time (OR 0.95; 9...
This was a single-institution study and only patients who answered the questionnaire were included in the study....
A significant proportion of patients have major low anterior resection syndrome at baseline and after successful treatment for anal cancer. Having major low anterior resection syndrome at baseline was...
ANTECEDENTES:Existe un conocimiento limitado sobre la función intestinal, sexual y urinaria a largo plazo después de la terapia de modalidad combinada para el cáncer anal de células escamosas.OBJETIVO...
Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responder...
Patients underwent baseline...
In total, 160 patients with resectable gastroesophageal junction adenocarcinomas were prospectively investigated by PET scanning. Eighty-five patients (53%) were excluded. Seventy-five eligible patien...
The primary endpoint of the study to increase the R0 resection rate in metabolic NR was not met. PET response after induction CTX is prognostic for outcome with a prolonged OS and DFS in PET responder...
NCT00002014-000860-16....
Facial aging involves multilevel changes, extending from the skin to deep support structures. A comprehensive treatment approach targeting the many aspects of facial dynamics and architecture is often...
To explore the integration of botulinum toxin type A (BoNT-A) into multimodal aesthetic treatment plans....
This article reviews evidence supporting the combination of BoNT-A with other minimally invasive cosmetic therapies, including dermal fillers, lasers, and energy-based devices as well as with plastic ...
Combination treatment protocols including BoNT-A demonstrate higher patient satisfaction and retention rates compared to monotherapy or sequential treatments. Some guidelines for sequencing of treatme...
Integrating BoNT-A into a larger aesthetic treatment plan is crucial for achieving natural and satisfying results in facial rejuvenation. Evidence supports better outcomes when incorporating with both...
Monotherapy with autologous expanded CD4...
We conducted a three-arms clinical trial to explore the efficacy and safety of the combined treatment with Tregs and rituximab in paediatric patients with T1DM. The patients were allocated to three gr...
At month 24, as compared with the control, both treatment groups remained superior in the area under the curve of C-peptide mixed meal tolerance test, whereas in the analysis of all visits only the co...
Over 2 years, combined therapy with Tregs and rituximab was consistently superior to monotherapy in delaying T1DM progression in terms of C-peptide levels and the maintenance of remission....
Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resecti...
Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relativel...
Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to p...
Loop diuretics are the cornerstone of the treatment of volume overload in decompensated heart failure. However, often complete decongestion cannot be achieved rapidly with loop diuretics alone, partly...
Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have limited efficacy in treating advanced hepatocellular carcinoma (HCC). The synergistic effect of systemic therapy and radia...
This retrospective observational study analyzed the medical records of 194 patients with Barcelona Clinic Liver Cancer stage C HCC who were admitted to our center from August 2018 to June 2022 and rec...
A total of 76 patients diagnosed with advanced-stage HCC and treated with ICIs and antiangiogenic therapy were included in the study, with 33 patients in the RT group and 43 patients in the non-RT gro...
In comparison to the combination of ICIs and antiangiogenic therapy, the inclusion of RT has been observed to improve the DCR and survival outcomes in patients with advanced-stage HCC. The safety prof...